一种神经免疫大脑组合模型,用于研究家族性阿尔茨海默病的病理生理学
Andrea Becerra-Calixto1, Anik Banerjee1, Huihui Fan1
1Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Journal of neuroinflammation
|October 9, 2025
概括
研究人员使用人类细胞开发了一种新的神经免疫组合模型来研究阿尔茨海默病 (AD). 这个模型成功地复制了关键的AD病理,包括粉样斑块和神经炎症,为疾病机制提供了新的见解.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 干细胞生物学 干细胞生物学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特点是粉样蛋白和蛋白的积累,神经炎症和神经元死亡.
- 微质在阿尔茨海默氏症的发病过程中发挥着关键作用,通过细胞和细胞因子的产生影响粉样蛋白病理和神经炎症.
- 现有的3D细胞培养模型往往缺乏微质,限制了它们完全回顾AD病理生理学的能力.
研究的目的:
- 开发一种新的神经免疫组合模型,将人类大脑器官 (COs) 与诱导的微状细胞 (iMGs) 结合起来.
- 调查该模型在复制阿尔茨海默病的炎症和病理特征方面的实用性.
主要方法:
- 通过联合培养大脑器官 (COs) 与来自家族AD患者iPSCs (PSEN2突变) 的诱导微状细胞 (iMGs) 开发了一种神经免疫组合物.
- 培养了120天的组合体,以便进行细胞集成和疾病建模.
- 分析了组织学,功能和转录特征,以评估AD类病理和神经炎症.
主要成果:
- 在120天的培养后,成功地将IMG与大脑器官集成在一起.
- 观察到类似于粉样斑块和神经纤维细胞的组织学特征.
- 显示出一种促炎性环境,其微质的细胞能力降低,神经炎症和亡基因表达增强.
结论:
- 开发的神经免疫组合模型有效地复制了阿尔茨海默病的炎症表型和粉样病理特征.
- 这种人类衍生的3D模型为研究AD病理生理学,特别是微质的作用提供了宝贵的平台.
- 该模型能够回顾AD的关键特征,为未来的药物查和治疗开发提供了潜力.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.4K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
44.2K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
